Impact of a Short-term Treatment With Canagliflozin (Canacardia-HF)

Sponsor
Université de Sherbrooke
Study ID
NCT03298009
Status
Withdrawn

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Canagliflozin 100mg — DRUG
    2-week intervention
  • Placebo oral capsule — DRUG
    2-week intervention
  • PET imaging — RADIATION
    1 day postprandial metabolic protocol at the end of treatment: CT scan followed by dynamic and pancorporel imaging

Study Details

It is a mechanistic proof-of-concept study to demonstrate how SGLT-2 inhibitors (Canagliflozin) may have a beneficial role on cardiac energetic efficiency. Patients with type 2 diabetes and with HF diagnosed for at least 3 months will be selected. The participants will be randomized to a double-blind, crossover 2-week placebo vs. Cana 100 mg once daily, an interventional trial with a one-month washout period in between. At the term of the two-week placebo and canagliflozin treatment periods (visits 2 and 4), each participant will undergo an identical postprandial metabolic study with positron emission tomography (PET) and stable isotopic tracer methods.

Key Dates

Start date
May 1, 2018
Status verified
Dec 2024
Primary completion
Jun 30, 2018
Completion
Jun 30, 2018

Study Design

Enrollment
0 participants (actual)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE

Arms

  • Placebo Comparator: Treatment 1
    placebo oral capsule will be administered once daily, for 2 weeks
  • Experimental: Treatment 2
    Canagliflozine 100mg once daily, for 2 weeks

Primary Outcome Measure

Change to be observed with canagliflozin on myocardial dietary fatty acid uptake [ Time Frame: 3 months ]

Related Studies